[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"notifications-list":3,"$f1w31y6o82d84k":5},{"data":4},[],{"data":6,"error":11},{"id":7,"documentId":8,"slug":9,"name":10,"medical_code":11,"short_description":12,"alternate_name":11,"disambiguating_description":11,"citations":13,"drugs":32,"specialties":38,"cover":11},922,"tys3q7xm09j90vg548s4x5up","cytochrome-p450-1a-inducers","Cytochrome P450 1A Inducers",null,"The CYP1A subfamily comprises CYP1A1 and CYP1A2, cytochrome P450 monooxygenases that oxidise fatty acids, steroid hormones and vitamins as well as many xenobiotics, inserting one atom of molecular oxygen into the substrate and reducing the second to water with two electrons supplied by NADPH through cytochrome P450 reductase. Drugs in this class induce that activity - UniProt records CYP1A1 as induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin and CYP1A2 as induced by nicotine, omeprazole, phenobarbital, primidone and rifampicin - so substrates of the subfamily are cleared faster and their exposure falls. FDA grades that consequence and defines an inducer by it: strong and moderate index inducers decrease the AUC of sensitive substrates of a given metabolic pathway by at least 80 percent and by 50 to under 80 percent respectively. A drug belongs here because its recorded effect on CYP1A is induction, not inhibition; as MED-RT populates the class, its one member is osimertinib.",[14,20,24,28],{"claims":15,"source":16,"licence":17,"source_url":18,"retrieved_at":19},"CYP1A1 as a cytochrome P450 monooxygenase metabolising fatty acids, steroid hormones and vitamins; the monooxygenase mechanism; INDUCTION by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD).","UniProtKB P04798","not stated on source page","https:\u002F\u002Frest.uniprot.org\u002Funiprotkb\u002FP04798.json","2026-09-19",{"claims":21,"source":22,"licence":17,"source_url":23,"retrieved_at":19},"CYP1A2 as a cytochrome P450 monooxygenase metabolising fatty acids, steroid hormones and vitamins; the monooxygenase mechanism; INDUCTION by nicotine, omeprazole, phenobarbital, primidone and rifampicin.","UniProtKB P05177","https:\u002F\u002Frest.uniprot.org\u002Funiprotkb\u002FP05177.json",{"claims":25,"source":26,"licence":17,"source_url":27,"retrieved_at":19},"'Strong and moderate index inducers are drugs that decrease the AUC of sensitive substrates of a given metabolic pathway by >=80 percent and >=50 to \u003C80 percent, respectively.' - the FDA definition of an inducer, stated as a fall in substrate exposure.","FDA, Drug Development and Drug Interactions | Table of Substrates, Inhibitors and Inducers","https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-interactions-labeling\u002Fdrug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers",{"claims":29,"source":30,"licence":17,"source_url":31,"retrieved_at":19},"Class membership: osimertinib.","RxNav RxClass class members (MED-RT), classId N0000191624","https:\u002F\u002Frxnav.nlm.nih.gov\u002FREST\u002Frxclass\u002FclassMembers.json?classId=N0000191624&relaSource=MEDRT&rela=has_MoA",[33],{"id":34,"documentId":35,"slug":36,"name":37,"active_ingredient":37,"dosage_form":11,"administration_route":11},1608,"u5xcptmcrtajlray2rh0djj0","albendazole","Albendazole",[]]